The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity
Scragg J., Koutoukidis DA., Dirksen C., Heitmann BL., Jebb SA.
Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are weight management medications, achieving up to 15%–25% weight loss in clinical trials. Given their effectiveness and potential for scalability, GLP1-RAs are a welcome treatment option for obesity. However, not everyone who could benefit may be able to afford or want to use GLP1-RAs. There are limited data on adherence beyond clinical trials or on how to optimize adjunct behavioral therapy. There is little support offered after GLP1-RA cessation, where weight regain is marked. Without increased accessibility and lower costs, the rollout of GLP1-RAs may widen inequalities. Currently, GLP1-RAs do not offer a sustainable solution to the public health pressures caused by obesity, where prevention remains crucial. To take the best advantage of GLP1-RAs, we need to deploy them in ways that are cost effective, sustainable for healthcare systems, and equitable for societies.